A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

Trial Identifier: D3254C00001
Sponsor: AstraZeneca
Start Date: July 2020
Primary Completion Date: May 2025
Study Completion Date: December 2026

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AR Rosario, AR, 2000
AT Innsbruck, AT, 6020
BE Brussel, BE, 1070
BE Edegem, BE, 2650
CN Chengdu, CN, 610041
CN Tianjin, CN, 300020
CN Xiamen, CN, 361015
CN Zhengzhou City, CN, 450008
DE Hannover, DE, 30625
DE Kirchheim, DE, 73230
DE Mannheim, DE, 68167
DK København Ø, DK, 2100
ES Santander, ES, 39010
FR Lille, FR, 59037
FR PESSAC, FR, 33604
FR Strasbourg, FR, 67091
FR Suresnes Cedex, FR, 92151
FR Toulouse, FR, 31059
GB London, GB, W2 1NY
IL Haifa, IL, 34362
IL Holon, IL, 58100
IL Jerusalem, IL, 91120
IL Kfar Saba, IL, 44218
IL Petah Tiqva, IL, 49100
IL Ramat Gan, IL, 5265601
IL Rehovot, IL, 76100
IL Tel-Aviv, IL, 64239
IN Ahmedabad, IN, 380013
IN Ajmer, IN, 305001
IN Delhi, IN, 110029
IT Bologna, IT, 40138
JP Chiba-shi, JP, 260-0852
JP Hamamatsu-shi, JP, 431-3192
JP Ichikawa-shi, JP, 272-8516
JP Kawasaki-shi, JP, 211-8510
JP Nishinomiya-shi, JP, 663-8501
JP Osaka-shi, JP, 530-8480
JP Sendai-shi, JP, 980-8574
KR Seoul, KR, 5505
NL Rotterdam, NL, 3015 GD
PL Chęciny, PL, 26-060
PL Gdańsk, PL, 80-214
PL Łódź, PL, 90-153
US, CA La Jolla, CA, US, 92037
US, GA Atlanta, GA, US, 30324
US, MD Bethesda, MD, US, 20892
US, MI Ann Arbor, MI, US, 48105
US, NC Durham, NC, US, 27705
US, OH Cleveland, OH, US, 44106
US, OH Columbus, OH, US, 43212
US, UT Salt Lake City, UT, US, 84112